Saga Lifesciences Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Saga Lifesciences Limited Pharmaceutical Export Portfolio Dataset — 14 Products, $7.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Saga Lifesciences Limited — Pharmaceutical Exporter Profile (2026) | 14 Products, $7.5M Trade | TransData Nexus

Saga Lifesciences Limited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $7.5M Total Trade · DGFT Verified

Saga Lifesciences Limited is an Indian pharmaceutical exporter with a total trade value of $7.5M across 14 products in 8 therapeutic categories. Based on 300 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cefixime ($2.4M), Vitamin ($2.3M), Tramadol ($500.0K).

Saga Lifesciences Limited — Export Portfolio & Destination Treemap

Saga Lifesciences Limited pharmaceutical export portfolio — 14 products across 8 therapeutic categories. Source: Indian Customs (DGFT).

Who is Saga Lifesciences Limited? — Company Overview & Market Position

Saga Lifesciences Limited, established on July 10, 2019, is a public limited company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24239GJ2019PLC109035. With an authorized and paid-up capital of ₹10 million, Saga Lifesciences has demonstrated consistent growth since its inception. The company employs approximately 221 professionals, reflecting its expanding operations. Its manufacturing facility spans over 11,000 square meters and adheres to global Good Manufacturing Practices (GMP), holding certifications from international regulatory bodies such as the European Union (EU) GMP, Therapeutic Goods Administration (TGA) Australia, Health Canada, and the World Health Organization (WHO) GMP. Saga Lifesciences exports its products to over 40 countries, including regions in Europe, Asia, Latin America, Africa, and Canada, underscoring its significant global footprint.

What Does Saga Lifesciences Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Cefixime$2.4M 2Vitamin

Product Portfolio — Top 14 by Export Value

Saga Lifesciences Limited exports 14 pharmaceutical products across 8 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cefixime	Advanced Antibiotics	$2.4M	47	1.4%	6
2	Vitamin	Nutritional Supplements	$2.3M	106	1.6%	11
3	Tramadol	Analgesics & Antipyretics	$500.0K	10	0.1%	2
4	Itraconazole	Antifungals	$474.6K	24	1.7%	14
5	Dextromethorphan	Respiratory & OTC	$448.0K	27	3.0%	8
6	Omega	Nutritional Supplements	$400.0K	8	2.1%	5
7	Ambroxol	Respiratory & OTC	$241.9K	34	1.6%	13
8	Glucosamine	Nutritional Supplements	$198.4K	6	1.5%	15
9	Collagen	Nutritional Supplements	$152.4K	6	6.5%	4
10	Torsemide	Diuretics	$106.8K	13	0.6%	10
11	Chondroitin	Nutritional Supplements	$103.2K	3	2.0%	11
12	Biotin	Vitamins & Supplements	$97.8K	4	6.4%	2
13	Benzylpenicillin	Advanced Antibiotics	$92.2K	6	2.4%	3
14	Clonazepam	CNS & Psychiatric	$39.8K	6	0.0%	12

Saga Lifesciences Limited exports 14 pharmaceutical products across 8 therapeutic categories with a total export value of $7.5M. The top category is Nutritional Supplements (41.7% of portfolio), followed by Advanced Antibiotics (32.7%), indicating a concentrated portfolio with the top 5 products accounting for 80.8% of total export value.

Saga Lifesciences Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Saga Lifesciences operates a state-of-the-art manufacturing facility located in Ahmedabad, Gujarat, India. The plant covers an area exceeding 11,000 square meters and is compliant with international GMP standards. It has been approved by several international regulators, including the EU GMP, TGA Australia, Health Canada, and WHO GMP. The facility specializes in the production of a diverse range of finished pharmaceutical formulations, including tablets, capsules, dry syrups, oral powders, liquids, injections, and ointments. This extensive product portfolio caters to both general formulations and specialized segments such as cephalosporins. The plant's capacity and capabilities enable Saga Lifesciences to meet the demands of various international markets effectively.

3Key Leadership

The leadership team at Saga Lifesciences Limited comprises several key individuals:

Viranchi Arvindbhai Shah: Director
Vinit Arvindbhai Shah: Director
Rushabh Vinit Shah: Director
Ruchir Vinitbhai Shah: Director
Vishal Harilal Haswani: Director
Sanjaykumar Jasvantlal Shah: Director

These directors collectively oversee the strategic direction and operational management of the company, contributing to its growth and expansion in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Saga Lifesciences Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Saga Lifesciences Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility holds certifications from international regulatory bodies such as the EU GMP, TGA Australia, Health Canada, and WHO GMP, facilitating access to these markets. Additionally, Saga Lifesciences has dedicated offices and marketing teams in Australia, Vietnam, Ghana, and Latin America, indicating a strategic approach to market penetration and regulatory compliance in these regions.

2Emerging Markets

Saga Lifesciences Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's global partnerships include dedicated offices in Australia, Vietnam, Ghana, and Latin America, with a focus on regions such as Honduras and Venezuela. These strategic expansions enable Saga Lifesciences to leverage the World Health Organization's (WHO) prequalification program, enhancing access to these markets and reinforcing its commitment to providing quality pharmaceutical products globally.

3Geographic Strategy

Saga Lifesciences Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Saga Lifesciences Limited's manufacturing facility is registered with the U.S. Food and Drug Administration (FDA), indicating compliance with FDA regulations for pharmaceutical manufacturing. The company has filed Abbreviated New Drug Applications (ANDAs) for its products, facilitating market access in the United States. While specific details regarding Drug Master File (DMF) filings and inspection history are not publicly disclosed, the FDA registration and ANDA filings suggest adherence to FDA standards and a commitment to maintaining product quality and safety.

2WHO & EU GMP

Saga Lifesciences Limited's manufacturing facility holds certifications from the World Health Organization (WHO) Good Manufacturing Practices (GMP) and the European Union (EU) GMP. These certifications attest to the company's adherence to international quality standards and regulatory requirements, ensuring that its products meet the stringent criteria set by these organizations. The WHO GMP certification, in particular, facilitates access to markets in developing countries, while the EU GMP certification is essential for trade within the European Union.

3CDSCO & Indian Regulatory

Saga Lifesciences Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Saga Lifesciences Limited operates in a competitive pharmaceutical industry, with numerous companies offering similar product portfolios. While specific market share data for Saga Lifesciences' competitors is not publicly available, the company's diverse product range and international certifications position it favorably in the market. The establishment of dedicated offices and marketing teams in key regions, such as Australia, Vietnam, Ghana, and Latin America, indicates a strategic approach to market penetration and competitive positioning.

2Key Differentiators

Saga Lifesciences Limited distinguishes itself through its ultramodern manufacturing facility, which complies with international GMP standards and holds certifications from regulatory bodies such as the EU GMP, TGA Australia, Health Canada, and WHO GMP. The company's extensive and diverse product portfolio, encompassing solid oral dosage forms, liquids, injections, and ointments, caters to a wide range of therapeutic needs. Additionally, Saga Lifesciences' in-house formulation and development wing enables the company to develop advanced formulations bio-equivalent to innovator drugs, enhancing its competitive edge.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Saga Lifesciences Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Saga Lifesciences Limited has demonstrated a strong track record in pharmaceutical manufacturing, with an estimated annual revenue of $19.6 million and a consistent year-over-year growth rate of 30% since its inception. The company's manufacturing facility is certified by international regulatory bodies, including the EU GMP, TGA Australia, Health Canada, and WHO GMP, indicating a high level of reliability and adherence to global quality standards. Additionally, Saga Lifesciences has commercialized and registered over 200 products successfully, reflecting its capability and consistency in delivering quality pharmaceutical formulations.

2Certifications to Verify

Importers should verify the following certifications to ensure the quality and compliance of Saga Lifesciences Limited's products:

FDA Registration: Confirm the company's registration with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulations.

WHO GMP Certification: Verify the World Health Organization's Good Manufacturing Practices certification to ensure adherence to international

Frequently Asked Questions — Saga Lifesciences Limited

How many pharmaceutical products does Saga Lifesciences Limited export from India?

Saga Lifesciences Limited exports 14 pharmaceutical products across 8 therapeutic categories. The top exports are Cefixime ($2.4M), Vitamin ($2.3M), Tramadol ($500.0K), Itraconazole ($474.6K), Dextromethorphan ($448.0K). Total export value is $7.5M.

What is Saga Lifesciences Limited's total pharmaceutical export value?

Saga Lifesciences Limited's total pharmaceutical export value is $7.5M, based on 300 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Saga Lifesciences Limited cover?

Saga Lifesciences Limited exports across 8 therapeutic categories. The largest are Nutritional Supplements (41.7%, 5 products), Advanced Antibiotics (32.7%, 2 products), Respiratory & OTC (9.2%, 2 products).

Get Full Saga Lifesciences Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.